Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 111Active not recruiting 37Unknown 28Terminated 28Recruiting 25Withdrawn 6Not yet recruiting 6Suspended 1Enrolling by invitation 1

Sponsor Class

OTHER 5OTHER_GOV 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Breast 6Other 1

Conditions

Breast Neoplasms 6Sexual Dysfunctions, Psychological 1Neoplasms 1Neoplasm Metastasis 1Muscle Neoplasms 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1HER2-positive Breast Cancer 1Chronic Pain 1

Interventions

Trastuzumab 16pertuzumab 14Capecitabine 14Docetaxel 12pyrotinib 11Cyclophosphamide 11Standard of Care 10Paclitaxel 10Letrozole 10trastuzumab deruxtecan 9Radiotherapy 9Carboplatin 9Fulvestrant 8Drug Therapy 8sacituzumab govitecan 7dalpiciclib 7exemestane 6eribulin 6Tamoxifen 6Epirubicin 6Anastrozole 6pembrolizumab 5palbociclib 5abemaciclib 5Surveys and Questionnaires 5Neoadjuvant Therapy 5Aromatase Inhibitors 5camrelizumab 4Sentinel Lymph Node Biopsy 4Doxorubicin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × Breast Neoplasms × Anastrozole × Clear all
NCT07596212 2026-05-19

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

University of Illinois at Chicago

Phase 1/2 Not yet recruiting
100 enrolled
BreastOther

Breast Neoplasms, Sexual Dysfunctions, Psychological

NCT07163481 2025-09-16

SoGreat

Hunan Cancer Hospital

Phase 1 Not yet recruiting
12 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Fujian Cancer Hospital

Phase 2 Not yet recruiting
200 enrolled
Breast

Breast Neoplasms

NCT06223698 2025-04-20

SWE-Switch

Region Örebro County

Phase 3 Not yet recruiting
3,832 enrolled
Breast

Breast Neoplasms

NCT06810492 2025-03-17

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

Hubei Cancer Hospital

Phase NA Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

NCT06154590 2023-12-04

NASBP-B-09

Paradyne Networks A Foundation

Not yet recruiting
100 enrolled
Breast

Breast Neoplasms, Neoplasms, Muscle Neoplasms, Chronic Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡